Press Release Details

View all news

What Are the Risks and Benefits of Low-Dose Aspirin?

06/03/2020

Low-dose aspirin significantly lowers cardiovascular disease risk but increases the risk of bleeding, according to a review published in the British Journal of Clinical Pharmacology.

Low-dose aspirin significantly lowers cardiovascular disease risk but increases the risk of bleeding, according to a review published in the British Journal of Clinical Pharmacology.

Investigators conducted the review because the overall balance between risks and benefits of taking aspirin has been unclear. The team pooled information from analyses of all relevant observational studies and randomized controlled trials.

Use of low-dose aspirin in people without cardiovascular disease was associated with a 17% lower incidence of cardiovascular events (such as non-fatal heart attacks, non-fatal strokes, or cardiovascular-related deaths). Low-dose aspirin use was also associated with a 47% higher risk of gastrointestinal bleeding and a 34% higher risk of intracranial bleeding.

“These risks and benefits need to be weighted in formal decision analyses to guide aspirin use in primary prevention,” said co-author Lee Smith, MSc, PhD, of Anglia Ruskin University, in the UK.

The authors noted that although many dozens of health effects besides cardiovascular disease and bleeding have been assessed, evidence for these remains weak and therefore should not be a major consideration when deciding whether to use low-dose aspirin.

Peer Reviewed                       Review                        Human

Additional Information

Link to Study: https://onlinelibrary.wiley.com/doi/10.1111/bcp.14310

About Journal 

Published on behalf of the British Pharmacological Society, the British Journal of Clinical Pharmacology features papers and reports on all aspects of drug action in humans: review articles, mini review articles, original papers, commentaries, editorials and letters. The Journal enjoys a wide readership, bridging the gap between the medical profession, clinical research and the pharmaceutical industry. It also publishes research on new methods, new drugs and new approaches to treatment. The Journal is recognised as one of the leading publications in its field. It is online only, publishes open access research through its OnlineOpen programme and is published monthly.

About Wiley

Wiley drives the world forward with research and education. Through publishing, platforms and services, we help students, researchers, universities, and corporations to achieve their goals in an ever-changing world. For more than 200 years, we have delivered consistent performance to all of our stakeholders. The Company's website can be accessed at www.wiley.com.

Penny Smith +44 (0) 1243 770448 (UK)
newsroom@wiley.com

Multimedia Files:

View all news